Literature DB >> 8489717

Inactivation of human immunodeficiency virus type I in human milk: effects of intrinsic factors in human milk and of pasteurization.

S L Orloff, J C Wallingford, J S McDougal.   

Abstract

Human milk was inoculated with human immunodeficiency virus type I (HIV-1) or with HIV-1-infected cells in volumes and containers typically used in human milk banks. The inoculated milk was pasteurized at 62.5 degrees C for 30 minutes in a water bath, i.e., conditions currently in use or proposed for human milk pasteurization. The process of HIV-1 inoculation and pasteurization effectively inactivated the infectivity of both cell-free HIV-1 and HIV-1-infected cells. No virus was recovered after the process, even after repeated subculturing in attempts to rescue the virus. Pasteurization reduced the infectious titer of cell-free HIV-1 and HIV-1-infected cells by more than 5 logs and 6 logs respectively. Human milk contains one or more components that inactive HIV-1 but that are not toxic for the cells used to replicate virus. These components have not been identified, but physical and solubility properties are consistent with characteristics of lipids.

Entities:  

Mesh:

Year:  1993        PMID: 8489717     DOI: 10.1177/089033449300900125

Source DB:  PubMed          Journal:  J Hum Lact        ISSN: 0890-3344            Impact factor:   2.219


  15 in total

1.  Role of fever in infection: has induced fever any therapeutic potential in HIV infection?

Authors:  R S Morton; S Rashid
Journal:  Genitourin Med       Date:  1997-06

2.  Breast Milk of HIV-Positive Mothers Has Potent and Species-Specific In Vivo HIV-Inhibitory Activity.

Authors:  Angela Wahl; Caroline Baker; Rae Ann Spagnuolo; Lisa W Stamper; Genevieve G Fouda; Sallie R Permar; Katie Hinde; Louise Kuhn; Lars Bode; Grace M Aldrovandi; J Victor Garcia
Journal:  J Virol       Date:  2015-08-19       Impact factor: 5.103

3.  Human milk banking.

Authors:  Jh Kim; S Unger
Journal:  Paediatr Child Health       Date:  2010-11       Impact factor: 2.253

4.  Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids.

Authors:  Shamim H Kazmi; Julian R Naglik; Simon P Sweet; Robert W Evans; Siobhan O'Shea; Jangu E Banatvala; Stephen J Challacombe
Journal:  Clin Vaccine Immunol       Date:  2006-08-23

5.  Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants.

Authors:  Louise Kuhn; Daria Trabattoni; Chipepo Kankasa; Moses Sinkala; Francesca Lissoni; Mrinal Ghosh; Grace Aldrovandi; Don Thea; Mario Clerici
Journal:  J Pediatr       Date:  2006-11       Impact factor: 4.406

6.  Human immunodeficiency virus type 1-infected cells in breast milk: association with immunosuppression and vitamin A deficiency.

Authors:  R W Nduati; G C John; B A Richardson; J Overbaugh; M Welch; J Ndinya-Achola; S Moses; K Holmes; F Onyango; J K Kreiss
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

7.  Milk sharing and formula feeding: Infant feeding risks in comparative perspective?

Authors:  Karleen D Gribble; Bernice L Hausman
Journal:  Australas Med J       Date:  2012-05-31

Review 8.  Preventing postnatal transmission of HIV-1 through breast-feeding: modifying infant feeding practices.

Authors:  Nigel Rollins; Nicolas Meda; Renaud Becquet; Anna Coutsoudis; Jean Humphrey; Barbara Jeffrey; Siripon Kanshana; Louise Kuhn; Valeriane Leroy; Dorothy Mbori-Ngacha; James McIntyre; Marie-Louise Newell
Journal:  J Acquir Immune Defic Syndr       Date:  2004-02-01       Impact factor: 3.731

9.  Breastfeeding in HIV-positive women: What can be recommended?

Authors:  Mackenzie Slater; Elizabeth M Stringer; Jeffrey S A Stringer
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

10.  Human milk banking-facts and issues to resolve.

Authors:  Willemijn E Corpeleijn; Marijn J Vermeulen; Ineke van Vliet; Caroline Kruger; Johannes B van Goudoever
Journal:  Nutrients       Date:  2010-07-13       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.